Shasun Pharmaceuticals Ltd.- (Amalgamation) - Stock Valuation and Financial Performance

BSE: 524552 | NSE: SHASUNPHAR | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Shasun Pharma

M-Cap below 100cr DeciZen not available

Shasun Pharmaceuticals Ltd.- (Amalgamation) stock performance -

mw4me loader
P/E Ratio (SA):
64.50
Market Cap:
2,884.3 Cr.
52-wk low:
407.8
52-wk high:
432.1

Is an attractive stock to invest in?

1. Is a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Shasun Pharmaceuticals Ltd.- (Amalgamation) is a below average quality company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Shasun Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shasun Pharmaceuticals Ltd.- (Amalgamation) has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15TTM
ROCE % 16.3%14.5%1.9%4%14%4.7%14.3%6.6%9%7.6%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3574054324715315677367839351,0781,024
Sales YoY Gr.-13.3%6.7%9%12.7%6.9%29.8%6.4%19.4%15.4%-
Adj EPS 7.57.80.31.19.10.77.73.77.15.46.7
YoY Gr.-4.3%-96.7%323.1%722.7%-92%965.3%-51.9%93.2%-24.1%-
BVPS (₹) 37.343.246.639.743.135.346.850.255.465.366.8
Adj Net
Profit
35.937.61.35.343.73.542.320.940.432.545
Cash Flow from Ops. 30.853.147.7-3345.234.99.710.36675.6-
Debt/CF from Ops. 2.61.92.8-6.44.86.324.5398.17.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%15.2%13.6%15.4%
Adj EPS -3.5%-9.8%-11%-24.1%
BVPS6.4%8.7%11.7%17.9%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15TTM
Return on
Equity %
22.619.20.62.521.81.819.57.613.48.910.1
Op. Profit
Mgn %
19.416.55.511.813.86.99.18.71111.912.8
Net Profit
Mgn %
10.19.30.31.18.20.65.72.74.334.4
Debt to
Equity
0.40.50.61.111.30.91.41.71.50.3
Working Cap
Days
148157163181227244207223227238126
Cash Conv.
Cycle
77849291857959697167-14

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Shasun Pharmaceuticals Ltd.- (Amalgamation)

Standalone Consolidated
TTM EPS (₹) 6.7 6.7
TTM Sales (₹ Cr.) 1,024 1,289
BVPS (₹.) 66.8 67.2
Reserves (₹ Cr.) 438 440
P/BV 6.42 6.38
PE 64.50 63.83
From the Market
52 Week Low / High (₹) 407.80 / 432.05
All Time Low / High (₹) 3.20 / 432.05
Market Cap (₹ Cr.) 2,884
Equity (₹ Cr.) 13.5
Face Value (₹) 2
Industry PE 47.5

Management X-Ray of Shasun Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *24.2931.7228.1428.0624.2417.2812.2913.1318.4117.32
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Shasun Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15
Sales357.14404.70431.81470.83530.55567.13735.91782.76934.721,078.39
Operating Expenses 288338.03408.26471.61490.15528.22684.39714.63839.35957.31
Manufacturing Costs54.7954.9566.6659.8765.1674.0381.90100.75106.17114.23
Material Costs176.24222.59274.86279.32298.53351.98468.67484.96541.94628.32
Employee Cost 22.5029.0835.3544.8246.7251.6559.5276.7495.26114.11
Other Costs 34.4731.4231.4087.6079.7450.5674.3052.1795.99100.66
Operating Profit 69.1566.6723.55-0.7840.4038.9151.5268.1395.37121.08
Operating Profit Margin (%) 19.4%16.5%5.5%-0.2%7.6%6.9%7.0%8.7%10.2%11.2%
Other Income 2.444.5434.744.0526.181640.9613.6612.2713.92
Interest 5.345.777.4214.0520.2622.3430.4826.4941.5453.78
Depreciation 23.1525.0926.5326.9126.0224.2224.7331.6638.1536.85
Exceptional Items 0000000001.46
Profit Before Tax 43.1040.3424.34-37.6820.308.3637.2723.6327.9545.82
Tax 6.602.062.08-4.31-1.773.48-15.79-2.64-7.284.48
Profit After Tax 36.5038.2822.27-33.3722.064.8853.0626.2835.2341.35
PAT Margin (%) 10.2%9.5%5.2%-7.1%4.2%0.9%7.2%3.4%3.8%3.8%
Adjusted EPS (₹)7.67.94.6-6.94.61.09.64.66.26.9
Dividend Payout Ratio (%)22%21%22%0%22%30%25%32%16%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15

Equity and Liabilities

Shareholders Fund 179.32208.72225.18191.81208.22171.49259.67287.27315.87394.32
Share Capital 9.629.649.669.669.669.7111.0311.3311.3312.03
Reserves 169.70199.08215.52182.15198.56161.78248.65275.94304.54382.30
Minority Interest0000000000
Debt79.48102.77135.49209.91214.68195.95214.30370.53489.54520.97
Long Term Debt79.48102.77135.49209.91214.6835.9949.0598.53180.29163.82
Short Term Debt00000159.96165.25272309.25357.14
Trade Payables37.6756.7255.0477.96104.36117.62155.27176.05232.60248.28
Others Liabilities 57.0355.2952.0548.4961.5579.6383.7282.22100.62155.88
Total Liabilities 353.50423.49467.76528.16588.81564.69712.96916.071,138.621,319.44

Fixed Assets

Gross Block291.39317.93340.08355.14360.43401.94444.86542.51586.11773.41
Accumulated Depreciation116.64139.67164.72191.21213.23235.77250.53275.13309.49344.79
Net Fixed Assets174.75178.25175.36163.93147.20166.17194.33267.39276.62428.62
CWIP 2.2010.0639.1529.1731.284.9330.8180.86101.6965.96
Investments 5.8525.3943.6343.610.652.355.0450.9057.4262.44
Inventories44.9852.8448.9445.0654.57104.87110.69145.33183.86211.50
Trade Receivables91.83119.21124.50183.32187.28137.92197.06220.68285.11296.34
Cash Equivalents 5.018.555.687.5213.0510.656.633.8810.562.28
Others Assets28.8829.2030.5055.55154.79137.79168.41147.04223.36252.30
Total Assets 353.50423.49467.76528.16588.81564.69712.96916.071,138.621,319.44

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15
Cash Flow From Operating Activity 30.7953.0847.72-33.0245.1934.939.7110.3265.9575.60
PBT 43.1040.3424.34-37.6820.308.3637.2723.6327.9545.82
Adjustment 28.1731.5931.1835.8151.719.335.9543.5058.1280.29
Changes in Working Capital -32.61-14.95-4.28-30.06-24.4318.07-32.03-52.26-14.21-43.14
Tax Paid -7.87-3.91-3.52-1.09-2.39-0.83-1.49-4.56-5.91-7.37
Cash Flow From Investing Activity -31.85-55.57-69.29-19.86-23.29-16.82-48.50-146.96-140.30-139.85
Capex -26.49-36.42-51.85-4.88-10.01-20.05-58.28-151.30-168.08-143.14
Net Investments -5.79-19.54-18.240.02-0.20-1.700-2.70-6.251.62
Others 0.430.390.79-15-13.084.949.787.0434.021.66
Cash Flow From Financing Activity -8.886.0218.7054.73-16.38-18.7136.88133.5480.8156.30
Net Proceeds from Shares 14.122.22-1.52000.4648.9711.25038.50
Net Proceeds from Borrowing -17.53-21.867.8453.08000000
Interest Paid -5.34-5.77-7.42-14.04-18.77-18.07-20.13-38.90-41.08-47.62
Dividend Paid -7.83-13.73-5.08-5.650-4.81-10.78-2.55-8.51-6
Others 7.7045.1524.8821.342.393.7118.82163.75130.3971.42
Net Cash Flow -9.943.53-2.871.855.52-0.60-1.92-3.106.45-7.95
PARTICULARSMar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15
Ratios
ROE (%)23.1619.7610.28-16.0211.032.5724.729.6911.7911.71
ROCE (%)19.8916.089.41-6.199.827.5515.258.459.0610.79
Asset Turnover Ratio1.091.091.020.990.981.011.180.990.940.91
PAT to CFO Conversion(x)0.841.392.14N/A2.057.160.180.391.871.83
Working Capital Days
Receivable Days78919811412410281949695
Inventory Days46424135335052586265
Payable Days80777487111115106125138140

Shasun Pharmaceuticals Ltd.- (Amalgamation) Stock News

Shasun Pharmaceuticals Ltd.- (Amalgamation) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Shasun Pharma on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Shasun Pharma stood at ₹2,884.3.
The latest P/E ratio of Shasun Pharma as of 01-Jan-1970 05:30 is 64.50.
The latest P/B ratio of Shasun Pharma as of 01-Jan-1970 05:30 is 6.42.
The 52-week high of Shasun Pharma is ₹432.1 and the 52-week low is ₹407.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shasun Pharma is ₹1,024 ( Cr.) .

About Shasun Pharmaceuticals Ltd.- (Amalgamation)

Shasun Chemicals and Drugs Limited (SCDL) was incorporated in 1976 and is headquartered in Chennai, India.

Shasun Chemicals and Drugs manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities.

Shasun has also emerged as a key player in various service segments in the pharmaceutical field besides APIs and intermediaries, and is strengthening its offer of contract research, custom synthesis, contract manufacturing and contract formulation services to clients.

Shasun is one of the largest producers of Ibuprofen worldwide. The company offers derivatives of Ibuprofen like Ibuprofen Sodium, Ibuprofen Lysinate and S+Ibuprofen. It is also one of the major producers of Ranitidine and Nizatidine in the world. Its products are exported to countries across North America, Europe, Asia and Latin America.

Shasun in its endeavour to become a true one-stop shop for global pharma companies, is evolving its business model to become a complete service provider, offering services right from the discovery stage to manufacturing formulations.

The company has recently added finished formulations capability as forward integration, and has invested in large facility to cater to the international regulated market. It has tied up with multinational companies in the formulations space wherein it will be developing and supplying products for the US market. 

The recent acquisition of the business and facilities of Rhodia Pharma Solutions by Shasun's wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), UK equipped the company to evolve as a technology based service provider than as a contract manufacturing and research provider. Its services include innovative process research and development, rapid response small scale manufacture for clinical trial supply and full scale commercial manufacture of advanced intermediates and API’s, all with seamless technology transfer with and without GMP. The formulation unit at Puducherry has been approved by USFDA.

By integrating its facilities in India and UK, the company is trying to offer the benefits of operations in both the countries to its clients. The company has aligned its facilities so that while research can be conducted in India, development and manufacturing in kilo labs and pilot plant can be conducted either in UK or India and the optimal mix could be decided based on the regulatory, IP and cost. The company is planning to set up a multi-product pilot plant facility at Vizag, Andhra Pradesh, focusing on Contract Manufacturing Services business. In FY06, CRAMS business revenue has reached Rs 3430 million.   

Product range of the company includes:

  • Ibuprofen
  • Ibuprofen Derivatives
  • Ranitidine base  
  • Ranitidine
  • Nizatidine  
  • Methoxital
  • Isradipine  
  • Gabapentine  
  • Olanzapine  
  • Quinapril HCl  
  • Meprobamate

Subsidiary:

Shasun Pharma Solutions Ltd (SPSL) is the subsidiary of the company

Milestones:    1976-1990

  • Incorporated as a private limited company, Shasun Chemicals in Chennai
  • First production facility established at Velachery, Chennai, for manufacture of Analgin (antipyretic).
  • Second production facility was established at Puducherry for manufacture of Ibuprofen (anti-inflammatory) 

1990-2000

  • Third manufacturing unit set up at Cuddalore to manufacture the anti-ulcerative Ranitidine HCI
  • Shasun converted into a public limited company, incorporating its present name.
  • US subsidiary, Shasun Inc, is established
  • The company's shares were listed on Mumbai, Ahmedabad and Chennai stock exchanges.
  • Technology and joint marketing agreement signed with Nagase & Co, Japan for S+Ibuprofen
  • The company signed a technology agreement with Chircotech, UK, for S+Naproxen.
  • The company signed a joint venture agreement with Austin Chemical Company, USA.

2000-Present day

  • The company's exports exceeded Rs.100 cr.
  • Established a biotech laboratory in its R&D centre.
  • Signed a letter of intent with Eli Lilly for supply and manufacture of an anti-TB drug.
  • Multi Purpose Plant at Cuddalore was commissioned.
  • Completed setting up its new Research Centre.
  • Strategic partnership with Glenmark and Alpharma(now part of Actavis) for Development & Supply of Formulation products.
  • Completed its first ever acquisition of Rhodia Pharma Solutions business marking its advent in the Global supply arena 
  • 2009 - Commercial launch of recombinant streptokinase in India (June 09)
  • 2010 - The Company entered into the rapidly growing filed of Nanotechno by entering into collaboration with Nanoparticle Biochem
    Company has changed its name from Shasun Chemicals & Drugs Ltd. to Shasun Pharmaceuticals Ltd.
    Finished dosages sales grows 100% and reaches Rs. 50 crores
  • 2011 Formed 50:50 JV Shasun NBI LLC in USA with Nanoparticle Biochem
  • 2012 Sun Pharma won the patent battle against Novo-Nordisk in the US Supreme Court over its generic drug ‘Prandin&rsquo.

Award & Recognition:

  • Entrepreneur Award -S.Abhaya Kumar, Joint Managing Director, Shasun received an award, for being nominated as one of the Finalist for the Ernst & Young
  • Entrepreneur of the Year 2003, from L.K.Advani, Deputy Prime Minister of India, at New Delhi.  
  • Four Star Safety Award -British Safety Council after conducting an audit awarded 4 Star rating for Puducherry facility for the year 2002. 
  • IDMA Award 2002 -Shasun Cuddalore facility has been recognised for its Quality Excellence by Indian Drug Manufacturer's Association in 2002. 
  • First Award -First Award by Chemexcil for the year 1998 - 1999 for Outstanding Export performance.  IDMA Award 2000
  • Shasun has been recognized for its Quality Excellence by the Indian Drug Manufacturers Association in 2000. 
  • Top Award -Top Award for Outstanding Export performance from Chemexcil for the year 1999 - 2000.  
  • Trishul Award -Shasun has been recognized for its export achievements by the Government of India in the form of the Trishul Award in 1993 and Certificate of Merit in 1996. 
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.